BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. The BSA-based method of dose calculation was adopted without adequate investigation of its ...
We evaluated the efficacy of intraperitoneal (IP) carboplatin in combination with dose-dense paclitaxel (ddTCip) for suboptimal residual ovarian cancer. This was a phase 2 study to evaluate ddTCip.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results